Effects on cognitive functioning after olanzapine–ziprasidone crossover in recent-onset schizophrenia |
| |
| Authors: | KP Grootens NMJ van Veelen MM Sitskoorn BGC Sabbe J Peuskens JK Buitelaar RJ Verkes RS Kahn |
| |
| Institution: | a CWZ general hospital Nijmegen, The Netherlands, Postbus 9015, 6500 GS Nijmegen;b Donders Centre for Neuroscience, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;c Centre of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands;d University Psychiatric Centre, Catholic University of Leuven, Kortenberg, Belgium;e Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Belgium;f Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands |
| |
| Abstract: | IntroductionTo enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial.Experimental proceduresUsing a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance.ResultsAfter eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n = 11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n = 10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n = 18; mean 10.9 mg) or ziprasidone (n = 18; mean 88.9 mg) treatment had not improved further.DiscussionThe findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly. |
| |
| Keywords: | Schizophrenia Clinical trial Antipsychotics |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
